C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.435
-0.065 (-4.33%)
May 14, 2025, 10:16 AM - Market open
C4 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 39.78 | 35.58 | 20.76 | 31.1 | 45.79 | 33.2 | Upgrade
|
| Revenue Growth (YoY) | 98.56% | 71.44% | -33.25% | -32.08% | 37.93% | 55.25% | Upgrade
|
| Cost of Revenue | 115.18 | 110.64 | 117.71 | 117.84 | 94.67 | 78.44 | Upgrade
|
| Gross Profit | -75.39 | -75.05 | -96.95 | -86.75 | -48.88 | -45.25 | Upgrade
|
| Selling, General & Admin | 41.17 | 42.12 | 42.08 | 42.79 | 33.25 | 15.2 | Upgrade
|
| Operating Expenses | 41.17 | 42.12 | 42.08 | 42.79 | 33.25 | 15.2 | Upgrade
|
| Operating Income | -116.56 | -117.18 | -139.03 | -129.53 | -82.13 | -60.45 | Upgrade
|
| Interest Expense | - | - | -1.37 | -2.22 | -2.15 | -1.23 | Upgrade
|
| Interest & Investment Income | 8.02 | 9.03 | 6.03 | 4.29 | 2.27 | 0.3 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -5.68 | Upgrade
|
| EBT Excluding Unusual Items | -108.54 | -108.14 | -134.38 | -127.46 | -82.01 | -67.06 | Upgrade
|
| Merger & Restructuring Charges | - | -2.44 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.4 | 5.4 | 3.78 | -0.71 | -1.88 | 0.1 | Upgrade
|
| Other Unusual Items | - | - | -0.62 | - | - | - | Upgrade
|
| Pretax Income | -103.15 | -105.19 | -131.21 | -128.18 | -83.89 | -66.96 | Upgrade
|
| Income Tax Expense | 0.13 | 0.13 | 1.28 | - | - | -0.63 | Upgrade
|
| Net Income | -103.28 | -105.32 | -132.49 | -128.18 | -83.89 | -66.34 | Upgrade
|
| Net Income to Common | -103.28 | -105.32 | -132.49 | -128.18 | -83.89 | -66.34 | Upgrade
|
| Shares Outstanding (Basic) | 70 | 69 | 50 | 49 | 46 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 70 | 69 | 50 | 49 | 46 | 11 | Upgrade
|
| Shares Change (YoY) | 28.41% | 39.75% | 1.59% | 6.13% | 304.93% | 728.80% | Upgrade
|
| EPS (Basic) | -1.48 | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 | Upgrade
|
| EPS (Diluted) | -1.48 | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 | Upgrade
|
| Free Cash Flow | -80.5 | -65.34 | -108.55 | -111.44 | -88.24 | -67.9 | Upgrade
|
| Free Cash Flow Per Share | -1.15 | -0.94 | -2.19 | -2.28 | -1.92 | -5.97 | Upgrade
|
| Gross Margin | -189.51% | -210.92% | - | -278.96% | -106.76% | -136.30% | Upgrade
|
| Operating Margin | -292.99% | -329.30% | -669.83% | -416.56% | -179.39% | -182.10% | Upgrade
|
| Profit Margin | -259.60% | -295.96% | -638.34% | -412.19% | -183.23% | -199.83% | Upgrade
|
| Free Cash Flow Margin | -202.36% | -183.61% | -522.96% | -358.36% | -192.73% | -204.55% | Upgrade
|
| EBITDA | -114.73 | -115.36 | -137.15 | -127.86 | -80.64 | -58.83 | Upgrade
|
| EBITDA Margin | -288.40% | - | - | - | -176.13% | -177.23% | Upgrade
|
| D&A For EBITDA | 1.83 | 1.82 | 1.88 | 1.68 | 1.49 | 1.62 | Upgrade
|
| EBIT | -116.56 | -117.18 | -139.03 | -129.53 | -82.13 | -60.45 | Upgrade
|
| EBIT Margin | -292.99% | - | - | - | -179.39% | -182.10% | Upgrade
|
Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.